Vivos Therapeutics, Inc. (VVOS) shares are rising more than 59 percent on Monday morning trade after FDA granted 510 (K) market clearance for its modified mandibular repositioning nighttime appliance or mmRNA oral device for treating mild to moderate sleep apnea. This is intended to treat mild to moderate obstructive sleep apnea, sleep-disordered breathing, and snoring in adults.

Create Account

Dark

chart

exchange

RTTNews | Aug 23, 2021 10:45AM EDT

10:45 Monday, August 23, 2021 (RTTNews.com) - Vivos Therapeutics, Inc. (VVOS) shares are rising more than 59 percent on Monday morning trade after FDA granted 510 (K) market clearance for its modified mandibular repositioning nighttime appliance or mmRNA oral device for treating mild to moderate sleep apnea. This is intended to treat mild to moderate obstructive sleep apnea, sleep-disordered breathing, and snoring in adults.

The company expects that the FDA clearance will pave way for expanded insurance reimbursement coverage for the device.

Currently, VVOS is trading at $6.06, up 59.33 percent from the previous close of $3.84 on a volume of 91,324,870. For the 52-week period, the shares have traded in a range of $2.61-$14.41 on average volume of 388,196.

Read the original article on RTTNews ( https://www.rttnews.com/3220529/vivos-therapeutics-up-59-after-fda-market-clearance-for-mmrna-oral-device.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved